Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000257485 | SCV000324438 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-10-18 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000257485 | SCV000327380 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Center of Medical Genetics and Primary Health Care | RCV001172264 | SCV000987247 | pathogenic | Familial cancer of breast | 2020-04-08 | no assertion criteria provided | research | ACMG Guidelines 2015 criteria The BRCA2 variant p.Asn2101Metfs is a known pathogenic variant in exon 11in a non-functional domain after the BRCA2_REPEAT (N2051-2085L aa) functional domain and in a mutation hotspot region with 31 pathogenic variants (PM1 Pathogenic Moderate). This frameshift mutation disrupts the function of the downstream BRCA-2_helical domain (D2479- 2667S aa) (Yang et al., 2002) (PVS1 Pathogenic Very Strong; PS3 Pathogenic Strong). 1 pathogenic prediction from GERP versus no benign predictions supports its deleterious effect (PP3 Pathogenic Supporting). This variant is not found in GnomAD exomes neither in GnomAD genomes (PM2 Pathogenic Moderate). The variant has been classified as pathogenic by the ClinGen-approved ENIGMA expert panel (ClinVar SCV000324438.1) (PP5 Pathogenic Supporting). In our study this pathogenic variant was found in a 31-year- old female with unilateral breast cancer and a strong family history. Therefore, this variant was classified as a Pathogenic. |